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Secretary Hillary Clinton has made the
rights of women, especially those living in
low-income countries, a central theme of
her tenure at the United States Depart-
ment of State. During her recent 11-day
trip to sub-Saharan Africa, issues of
gender equality and empowering women
arguably had their highest profile ever [1],
and there is a clear commitment by both
the Secretary and the Obama administra-
tion to work aggressively toward achieving
the two major Millennium Development
Goals (MDGs) that specifically advocate
for women, namely MDG 3 ‘‘Promote
gender equality and empower women’’
and MDG 5 ‘‘Improve maternal health’’
(see http://www.un.org/millenniumgoals).
Because the neglected tropical diseases
(NTDs) are the most common infections
among the world’s poorest people [2],
including girls and women, there is now a
strong case to be made for controlling the
NTDs as a means of directly addressing
MDG 3 and MDG 5. Studies conducted
over the last two decades provide an
evidence base that the NTDs are important
factors that (i) impair reproductive health in
developing countries; (ii) increase the trans-
mission of sexually transmitted infections
(STIs); and (iii) promote stigma and gender
inequality (Table 1). For these reasons,
interventions focused on NTD control and
elimination could offer an opportunity
for improving the health and rights of girls
and women in the poorest countries of
Africa, Asia, and Latin America and the
Caribbean.
The Impact of NTDs on Female
Reproductive Health
Pregnancy and lactation place huge iron
demands on the mother and her child. A
1994 report from the World Health
Organization (WHO) concluded that a
woman living in a developing country is
practically always on the verge of iron
deficiency anemia either because of preg-
nancy, which requires the transfer of
300 mg of iron to the fetus during the
third trimester and an additional 500 mg
of iron to accommodate an increase in red
blood cell mass, or lactation, in which each
episode transfers 0.75 mg of iron from
mother to child [3]. Moreover, even
before she becomes pregnant, a woman
of childbearing age suffers substantial iron
losses from menstruation [3]. Anemia,
defined as a reduction in hemoglobin to
,11 g/dl in the first and third trimester
and ,10.5 g/dl in the second trimester,
creates a dangerous state of health for both
mother and child [4]. It is estimated that
20% of maternal deaths in Africa are
attributed to anemia, while simultaneously
anemia represents a key risk factor for
poor pregnancy outcome and low birth
weight [4,5]. It now appears that human
hookworm infection, one of the most
common NTDs affecting 576–740 million
people in developing countries, consider-
ably adds to the iron loss and anemia that
occurs during pregnancy [6]. An estimated
44 million pregnant women are infected
with hookworm at any one time [3],
including up to one-third of all pregnant
women in sub-Saharan Africa [7]. In
Africa and Latin America, hookworm is
a major contributor to anemia in preg-
nancy [7,8], while in Nepal and presum-
ably elsewhere in Asia hookworm is
responsible for 54% of cases of moderate
to severe anemia during pregnancy [9].
Not surprisingly, deworming during preg-
nancy has major beneficial effects in terms
of reduced maternal morbidity and mor-
tality, as well as improved perinatal
outcome [10,11], and most likely leads to
a reduction in maternal anemia. Such
studies have led to calls for including
deworming in antenatal packages in hook-
worm-endemic areas in developing coun-
tries [5,6,12].
There is also some evidence that
schistosomiasis in pregnancy contributes
to increased maternal morbidity and low
birth weight [13]. Like hookworm infec-
tion, schistosomiasis is an important cause
of anemia in Africa [5,14], but in addition,
schistosome eggs can be deposited in the
placenta where they cause inflammation,
and this feature may also contribute to
adverse maternal-fetal outcomes [13].
Therefore, there is a need for expanded
studies of praziquantel administration
during pregnancy to complement the
studies purporting a beneficial effect of
anthelmintic drugs for hookworm and
other soil-transmitted helminth infections.
In addition to adverse pregnancy out-
comes, both hookworm infection and
schistosomiasis contribute to infertility.
Since the 1920s, it has been noted that
chronic hookworm among women of
reproductive age causes amenorrhea and
sterility, and that both regular menses and
fertility could often be restored through
deworming [3]. In sub-Saharan Africa
there are an estimated 112 million people
infected with urinary tract schistosomiasis
caused by Schistosoma haematobium [15]. Up
to 75% of women with S. haematobium
infection are also at risk for infertility
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caused by the deposition of schistosome
eggs and the resulting granulomatous
inflammation in the uterus, fallopian
tubes, and ovaries [16–18]. There is
interest in potentially preventing the onset
of these inflammatory processes through
early intervention with praziquantel
[19–21].
It has also been noted that congenital
infections with some NTD pathogens can
occur commonly. Congenital toxoplasmo-
sis and malaria are the best-known
examples [22,23], but there is also now
evidence that congenital Chagas disease
occurs with high frequency among sero-
positive pregnant mothers, particularly
those with parasitemia [24,25]. Congenital
leishmaniasis has also been described
[26,27], as has lactogenic infection of
hookworm and strongyloidiasis [6,28].
Finally, pregnancy can result in host
immunomodulatory effects that could
affect the severity of both schistosomiasis,
leprosy, and presumably other NTDs
[29,30].
NTDs and STIs
Several NTDs are also STIs or, in some
cases, NTDs promote susceptibility to
other STIs. For example, trichomoniasis
is both an NTD and an STI with the
parasitic protozoan Trichomonas vaginalis,
which is now recognized as one of the
most common STIs in Africa and else-
where [31]. In the United States of
America, trichomoniasis is also an impor-
tant STI among poor and under-repre-
sented minority populations [32]. Female
genital schistosomiasis (especially of the
lower genital tract) has been identified as
an important co-factor in HIV transmis-
sion in rural areas of Africa where S.
haematobium and HIV/AIDS are co-en-
demic [16,33–35]. It has been suggested
that the schistosome egg granulomas
function as erosive or ulcerative lesions in
the cervix and vagina, possibly similar to
those caused by other STIs such as herpes
simplex virus-2 infection or syphilis. Such
lesions presumably facilitate HIV viral
entry, or possibly HIV entry, and replica-
tion is enhanced by the propensity of the
schistosome egg granulomas to cause
bleeding or serve as a repository of
CD4+ cells [16]. In any case, female
genital schistosomiasis has been shown in
a rural area of northern Zimbabwe to be
associated with a 3-fold risk of horizontal
HIV/AIDS transmission [34], furthering
the urgency to investigate praziquantel
treatment of this condition as a part of a
larger allied effort toward HIV/AIDS
prevention.
NTDs, Stigma, and Gender
Inequality
In her 2007 address to the WHO
Global Partners Meeting on NTDs, Mar-
garet Chan, the Director-General of
WHO, stated that ‘‘stigma and social
isolation, especially for women, compound
the misery and further embed people in
poverty’’ [36]. Previous articles in PLoS
Neglected Tropical Diseases have explored the
important social and economic conse-
quences of stigma associated with the
disfigurement of many NTDs, including
lymphatic filariasis (LF), onchocerciasis,
leishmaniasis, and the mycobacterial in-
fections (such as Buruli ulcer and leprosy
[37,38]), and indeed, emerging evidence
(summarized in a 2005 report commis-
sioned by WHO-Special Programme for
Research and Training in Tropical Dis-
eases [TDR]) suggests that women are
often particularly isolated and marginal-
ized by stigma-associated NTDs [39]. In
LF, lymphedema occurs more frequently
in women than in men [39,40], often with
involvement of the breasts and vulva
[39,41], but these clinical features fre-
quently go unnoticed because in some
developing countries the examination of
women is restricted to the arms and legs
[39,42]. A recent qualitative study of LF
from Sri Lanka has articulated the breadth
and depth of social stigma linked to LF
among women and includes evidence for
lost jobs and wages and abandonment by
family [38]. Similarly, African women are
disproportionately ostracized for Onchocerca
skin disease [43–45], and in South Asia
women are sometimes prevented from
seeking medical attention for kala-azar
(accounting for a higher disease burden
from this condition among women) [46].
In Afghanistan, cutaneous leishmaniasis
prevents mothers from holding their
children, while in Colombia this disease
is a contributing factor for spousal aban-
donment [46]. The social impact of
leprosy is also greater among women
[39,47,48], an observation that stimulated
the WHO Director-General to remark in
Table 1. Health Threats to Women Resulting from Neglected Tropical Diseases.
Health Condition Neglected Tropical Disease References
Reproductive Health
Infertility Urogenital schistosomiasis, hookworm [3,16–18]
Severe anemia of pregnancy/lactation and high maternal morbidity and mortality Hookworm (major), schistosomiasis (minor) [3–13]
Anemia associated with menstruation and amenorrhea Hookworm [3,6]
Congenital infection; lactogenic infection Chagas disease, leishmaniasis, strongyloidiasis,
hookworm
[6,22–28]
Low birthweight and/or premature birth from placental inflammation and maternal anemia Hookworm and other soil-transmitted helminth
infections, schistosomiasis
[10–13]
Exacerbation of disease during pregnancy Leprosy, schistosomiasis [29,30]
Sexually Transmitted Infections
HIV/AIDS Urogenital schistosomiasis [33–35]
Trichomoniasis Trichomoniasis [31,32]
Social Exclusion and Stigma
Limb, breast, skin, and genital deformities Lymphatic filariasis, Buruli ulcer, Onchocerca skin
disease, leprosy, leishmaniasis
[36–45]
Facial disfigurement Leishmaniasis, leprosy [36,46–48]
doi:10.1371/journal.pntd.0000559.t001
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woman with leprosy is told she can be fully
cured, can marry, have children, and will
not infect others. Just imagine the impact’’
[36].
Future Directions
Because of the dramatic impact of
NTDs on the health of women, especially
girls and women in their child-bearing
years, it is critically important that these
populations are included in current and
proposed large-scale interventions for
NTDs. Efforts to expand global deworm-
ing with benzimidazole anthelmintics
against soil-transmitted helminth infec-
tions and praziquantel against schistoso-
miasis should include pregnant women as
recommended in recently issued WHO
guidelines for helminth control [49]. At
the same time, there should be increased
efforts to conduct safety testing of iver-
mectin and diethylcarbamazine in preg-
nancy or during lactation, such as the one
study recently reported from Uganda [50],
in order to ensure that all women in their
reproductive years may one day become
eligible for mass drug administration
against onchocerciasis and LF, as well as
for integrated control against all of the
most common NTDs [2]. Similarly, there
is a need for additional operational
research on the beneficial effects of NTD
control on pregnancy outcome, and stud-
ies to examine the impact of praziquantel
and possibly other anthelmintics on re-
ducing HIV/AIDS transmission among
women in their reproductive years. Addi-
tional social science research on gender
inequalities for NTDs is also urgently
needed. Finally, it has been pointed out
that in developing countries women are
‘‘key agents of change’’ whose role could
be expanded to further promote social
mobilization, including ensuring compli-
ance in community-based drug distribu-
tion and treatment programs for NTDs as
well as in vector control [51]. Increasingly,
the NTD community needs to enlist the
support of women throughout the devel-
oping world as a critical part of ensuring
access to essential medicines against the
NTDs. Both the WHO’s Department of
Control of Neglected Tropical Diseases
and a new Global Network for Neglected
Tropical Diseases have placed the em-
powerment of women as a top priority in
its pursuit of widespread coverage for the
most common NTDs, including soil-trans-
mitted helminth infections, schistosomia-
sis, LF, and onchocerciasis [2], while new
initiatives devoted to research and devel-
opment by WHO-TDR are currently
championing gender issues [39]. Simulta-
neously, both WHO-TDR and nonprofit
product development partnerships, includ-
ing the Human Hookworm Vaccine
Initiative through the Sabin Vaccine
Institute, will champion the inclusion of
women in the clinical development of new
drugs, diagnostics, and vaccines. Such
activities create a robust opportunity to
prioritize the control of NTDs and NTD
research and development and designate
these activities as key enabling mecha-
nisms for advancing women’s reproductive
and maternal health.
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